Last reviewed 2026-05-27 · How we verify

Barnetil (SULTOPRIDE)

Phase 2 active Small molecule ✓ Verified May 2026

Barnetil (generic name: SULTOPRIDE) is a sultopride drug. It is currently in Phase 2 development.

Barnetil works by blocking the D(2) dopamine receptor, which helps regulate mood and emotional responses.

Barnetil is a small molecule with the synonyms SULTOPRIDA, SULTOPRIDE, and SULTOPRIDE. It has been studied in clinical trials for various conditions, including Major Depressive Disorder, Post Operative Nausea and Vomiting, Anorexia Nervosa, Clozapine-induced Hypersalivation, and Schizophrenia, with amisulpride being one of the interventions used.

Likelihood of approval

12.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
CNS / neurology attrition -3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	SULTOPRIDE
Drug class	sultopride
Target	D(2) dopamine receptor, D(3) dopamine receptor
Modality	Small molecule
Therapeutic area	Neuroscience
Phase	Phase 2

Mechanism of action

Think of dopamine like a messenger in your brain that helps you feel happy and motivated. When Barnetil blocks the D(2) receptor, it can help reduce excessive dopamine activity that may contribute to psychiatric symptoms. This can lead to improved mood and reduced anxiety.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Barnetil CI brief — competitive landscape report
Barnetil updates RSS · CI watch RSS

Frequently asked questions about Barnetil

What is Barnetil?

Barnetil (SULTOPRIDE) is a sultopride drug.

How does Barnetil work?

Barnetil works by blocking the D(2) dopamine receptor, which helps regulate mood and emotional responses.

What is the generic name of Barnetil?

SULTOPRIDE is the generic (nonproprietary) name of Barnetil.

What drug class is Barnetil in?

Barnetil belongs to the sultopride class. See all sultopride drugs at /class/sultopride.

What development phase is Barnetil in?

Barnetil is in Phase 2.

What does Barnetil target?

Barnetil targets D(2) dopamine receptor, D(3) dopamine receptor and is a sultopride.

Drug class: All sultopride drugs
Target: All drugs targeting D(2) dopamine receptor, D(3) dopamine receptor
Therapeutic area: All drugs in Neuroscience

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing